ATE249243T1 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents
Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelatInfo
- Publication number
- ATE249243T1 ATE249243T1 AT97902867T AT97902867T ATE249243T1 AT E249243 T1 ATE249243 T1 AT E249243T1 AT 97902867 T AT97902867 T AT 97902867T AT 97902867 T AT97902867 T AT 97902867T AT E249243 T1 ATE249243 T1 AT E249243T1
- Authority
- AT
- Austria
- Prior art keywords
- chelate
- toxin
- drug
- antibodies
- net load
- Prior art date
Links
- 239000013522 chelant Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Radiology & Medical Imaging (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58607596A | 1996-01-11 | 1996-01-11 | |
| PCT/US1997/000307 WO1997025069A1 (en) | 1996-01-11 | 1997-01-06 | Antibodies with reduced net positive charge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE249243T1 true ATE249243T1 (de) | 2003-09-15 |
Family
ID=24344206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97902867T ATE249243T1 (de) | 1996-01-11 | 1997-01-06 | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0873139B1 (enExample) |
| JP (2) | JP2000503301A (enExample) |
| KR (1) | KR100485240B1 (enExample) |
| AT (1) | ATE249243T1 (enExample) |
| AU (1) | AU730388B2 (enExample) |
| CA (1) | CA2242750C (enExample) |
| DE (1) | DE69724761T2 (enExample) |
| ES (1) | ES2206683T3 (enExample) |
| RU (1) | RU2219949C2 (enExample) |
| WO (1) | WO1997025069A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047903A1 (en) * | 2003-11-07 | 2005-05-26 | Upstate Usa. Inc. | A method for generating antibody conjugates that preserves antigen recognition |
| US20150344580A1 (en) * | 2012-06-05 | 2015-12-03 | Eldar Kim | Human Monoclonal Antibodies Against Human Chemokine Receptor CCR7 |
| KR102090849B1 (ko) | 2012-07-04 | 2020-03-19 | 에프. 호프만-라 로슈 아게 | 공유 결합된 항원-항체 접합체 |
| EP2869837B1 (en) | 2012-07-04 | 2016-09-14 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
| EP3339328A1 (en) * | 2012-07-04 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-biotin antibodies and methods of use |
| JP6602304B2 (ja) | 2014-01-03 | 2019-11-06 | エフ．ホフマン−ラ ロシュ アーゲー | 共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途 |
| EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
| PL3089996T3 (pl) | 2014-01-03 | 2021-12-13 | F. Hoffmann-La Roche Ag | Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| WO1988007553A1 (fr) * | 1987-03-26 | 1988-10-06 | Teijin Limited | Procede de preparation d'un complexe d'anticorps |
| EP0593452A1 (en) * | 1989-11-30 | 1994-04-27 | Mallinckrodt Medical, Inc. | Method for preparing a metal-radionuclide-labelled protein |
| US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| SE9100142L (sv) * | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
| US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
| DE69331319T2 (de) * | 1992-06-09 | 2002-08-08 | Neorx Corp., Seattle | Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren |
| JPH0853499A (ja) * | 1994-08-10 | 1996-02-27 | Green Cross Corp:The | キメラ抗体Ｆａｂ断片のオリゴマー体 |
-
1997
- 1997-01-06 AT AT97902867T patent/ATE249243T1/de active
- 1997-01-06 CA CA002242750A patent/CA2242750C/en not_active Expired - Fee Related
- 1997-01-06 ES ES97902867T patent/ES2206683T3/es not_active Expired - Lifetime
- 1997-01-06 DE DE69724761T patent/DE69724761T2/de not_active Expired - Lifetime
- 1997-01-06 EP EP97902867A patent/EP0873139B1/en not_active Expired - Lifetime
- 1997-01-06 KR KR1019980705339A patent/KR100485240B1/ko not_active Expired - Fee Related
- 1997-01-06 RU RU98115277/15A patent/RU2219949C2/ru not_active IP Right Cessation
- 1997-01-06 JP JP9525384A patent/JP2000503301A/ja active Pending
- 1997-01-06 AU AU16939/97A patent/AU730388B2/en not_active Ceased
- 1997-01-06 WO PCT/US1997/000307 patent/WO1997025069A1/en not_active Ceased
-
2012
- 2012-02-08 JP JP2012024825A patent/JP2012131808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU1693997A (en) | 1997-08-01 |
| DE69724761D1 (de) | 2003-10-16 |
| KR19990077198A (ko) | 1999-10-25 |
| DE69724761T2 (de) | 2004-08-05 |
| CA2242750A1 (en) | 1997-07-17 |
| CA2242750C (en) | 2007-03-27 |
| ES2206683T3 (es) | 2004-05-16 |
| JP2012131808A (ja) | 2012-07-12 |
| KR100485240B1 (ko) | 2006-10-24 |
| JP2000503301A (ja) | 2000-03-21 |
| EP0873139B1 (en) | 2003-09-10 |
| WO1997025069A1 (en) | 1997-07-17 |
| EP0873139A1 (en) | 1998-10-28 |
| AU730388B2 (en) | 2001-03-08 |
| RU2219949C2 (ru) | 2003-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2090700A1 (en) | Modified antibodies with controlled clearance time | |
| UA66857C2 (uk) | КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ | |
| ATE347378T1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| FR15C0033I2 (fr) | Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique | |
| EP0329184A3 (en) | Antimers and antimeric conjugation | |
| NO901986L (no) | Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler. | |
| BR0015506A (pt) | Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças | |
| BR0016339A (pt) | Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto | |
| NO20010021L (no) | Trifunksjonelt reagens for konjugering til et biomolekyl | |
| DE60113445D1 (de) | Substanzen mit verzweigten linkermolekülen | |
| ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| ATE192047T1 (de) | Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
| DE69223504D1 (de) | Bicycloazamakrocyclophosphon-Säure, Komplexe, Konjugate, Kontrastmittel und Herstellung | |
| DK0478631T3 (da) | Målsøgende midler | |
| FI933506A0 (fi) | Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel | |
| BR9913429A (pt) | Anticorpos bifuncionais e seu uso na objetivação de agentes antitumor | |
| BR9714945A (pt) | Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos | |
| NO954442L (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
| TR199700842T1 (xx) | �nsan DNase I Varyantlar�. | |
| Muzykantov | Conjugation of catalase to a carrier antibody via a streptavidinŐbiotin cross‐linker | |
| RU93053897A (ru) | Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения | |
| WO1998051792A8 (en) | Fac molecules and uses thereof | |
| MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0873139 Country of ref document: EP |